disease, and most patients with AIDS do not yet have access to antiretroviral drugs. Some patients whose 'gastric' conditions are not controlled with ranitidine can suffer from lack of access to a proton pump inhibitor. Perhaps our patients with diabetes might have better control with new oral hypoglycaemic drugs, although our woefully poor control of diabetes is mainly caused by socio-economic factors rather than lack of access to new drugs.
It has been estimated that successful drug therapy currently is directed at fewer than 500 targets.
Considering that the human genome contains some 30 000 genes, it is possible that its study could lead to at least 3000 to 5000 potential new targets for therapy.
Currently, predominant candidates include G proteincoupled receptor families and other receptors and related molecules, a wide range of enzymes including proteases, kinases and phosphatases, hormones, growth factors, chemokines, soluble receptors and related molecules, and many others. Exactly the same principles are being applied to the search for agents to interfere with key biochemical pathways in pathogens, based on information which is being obtained from the pathogen genome project. 4 Just as discoveries in the old disciplines of chemistry and biochemistry in the early 20th century took many years to translate into new drugs, so it will take time to learn how to realise the potential of the new discipline of genomics. But learn we must.
If a potential drug discovery/innovation/invention is not patented, it will never find its way into practice. With new drugs said to cost around $1 billion to bring to market, investment will only be made if patent protection is assured. If the degree of 'real innovation' must be predetermined, based on previous experience, valuable therapies may be lost. Whatever our differences of emphasis, the ultimate goal is the same: effective, accessible, affordable medicines for all.
